Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 1, 2006
Event: Entry into a Material Definitive Agreement involving a private placement of debt securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key metrics include:
- Total Proceeds: $5 million principal amount.
- Instrument: 6% Secured Convertible Notes due 2012.
- Interest Rate: 6% per annum, compounded annually, payable at maturity.
- Investors: Southpaw Credit Opportunity Master Fund LP ($2 million), 3V Capital Master Fund Ltd ($1.5 million), and Distressed/High Yield Trading Opportunities, Ltd ($1.5 million).
- Security: Notes are secured by substantially all of Nephros's assets.
- Conversion Terms: Initial conversion price of $2.10 per share.
- Dilution Cap: Aggregate shares issuable upon conversion and warrant exercise limited to 2,451,280 shares (approximately 19.9% of outstanding common stock).
Material Changes and Terms
The primary material change is the creation of a new direct financial obligation and potential equity dilution.
- Prepayment Warrants: If Nephros prepays the Notes on or before June 1, 2008, it must issue warrants to purchase three shares of Common Stock for every $20 principal amount prepaid, at an exercise price of $0.01 per share.
- Forced Conversion: Nephros may force conversion if the Common Stock trades at an average last sale price of at least 240% of the effective conversion price with sufficient daily volume.
- Registration Rights: Investors received demand and piggy-back registration rights for shares issuable upon conversion or warrant exercise.
Risks, Contingencies, and Events of Default
The Notes contain specific events of default that could render the principal and accrued interest immediately due and payable:
- Failure to pay principal or interest when due.
- Certain bankruptcy-related events.
- Material breach of representations, warranties, or certifications.
- Incurrence of Senior Debt (as defined in the Note).
- Acceleration of certain other debt.
- Rendering of certain judgments against Nephros.
Unregistered Sales: The issuance was exempt from registration under Section 4(2) of the Securities Act of 1933 and/or Regulation D, relying on the investors' status as sophisticated investors.
Investor Verification Checklist
- Verify the exact number of shares outstanding immediately prior to issuance to confirm the 19.9% dilution cap calculation.
- Review the definition of "Senior Debt" in the Note to understand restrictions on future borrowing.
- Assess the company's ability to service the 6% interest compounded annually until maturity in 2012.
- Examine the anti-dilution adjustment provisions to understand how future equity issuances might affect the conversion price.
- Confirm the status of the Registration Rights Agreement and any pending S-1 or S-3 filings for the convertible shares.